疫苗诱导免疫性血栓性血小板减少症治疗药物的抗血栓疗效与出血风险
本研究在VITT小鼠模型中比较多种抗凝药、IVIg及FcγRIIa阻断抗体IV.3对VITT IgG-PF4结合、血小板活化、血小板减少和血栓形成的影响;达那肝素是唯一在治疗剂量下减少VITT IgG-PF4结合的抗凝药,IVIg和除普通肝素外的所有抗凝药均保护VITT小鼠免于血栓形成,IV.3抗体可同时改善血栓形成和血小板减少。
要点
- 达那肝素在治疗剂量下是唯一减少VITT IgG-PF4结合的抗凝药。
- 达那肝素和高剂量普通肝素(10 U/mL)抑制血小板活化,但所有抗凝药均延长出血时间。
- IV.3抗体直接抑制FcγRIIa受体,可有效处理VITT小鼠模型中的血栓形成和血小板减少。
核心结论
- 达那肝素在治疗剂量下是唯一减少VITT IgG-PF4结合的抗凝药;IVIg和除普通肝素外的所有抗凝药保护VITT小鼠免于血栓形成;直接抑制FcγRIIa受体的IV.3抗体可有效处理VITT小鼠模型中的血栓形成和血小板减少。
- 研究结果强调需要动物模型研究来为临床医生选择治疗提供信息和更好指导,并为开发FcγRIIa受体阻断剂以预防VITT及其他FcγRIIa相关炎症性疾病中的血栓形成提供了有力证据。
研究设计与样本
- 研究在VITT小鼠模型中检查多种抗凝药(普通肝素、达那肝素、比伐卢定、磺达肝癸钠和阿加曲班)、IVIg及FcγRIIa受体阻断抗体IV.3的效果,聚焦VITT IgG-PF4结合、血小板活化、血小板减少和血栓形成。
主要发现
- 达那肝素在治疗剂量下是唯一减少VITT IgG-PF4结合的抗凝药,经亲和纯化抗PF4 VITT IgG验证。
- 达那肝素和高剂量普通肝素(10 U/mL)抑制血小板活化,但所有抗凝药均延长出血时间,且在本VITT动物模型中均未显著影响血小板减少。
- IVIg和除普通肝素外的所有抗凝药保护VITT小鼠免于血栓形成。
- 直接抑制FcγRIIa受体的IV.3抗体可有效处理VITT小鼠模型中的血栓形成和血小板减少。
临床怎么用
- 作者认为,研究结果强调需要动物模型研究来为临床医生选择治疗提供信息和更好指导。
- 作者认为,本研究为开发FcγRIIa受体阻断剂以预防VITT及其他FcγRIIa相关炎症性疾病中的血栓形成提供了有力证据。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Current guidelines for treating vaccine-induced immune thrombotic thrombocytopenia (VITT) recommend nonheparin anticoagulants and IV immunoglobulin (IVIg). However, the efficacy of these treatments remains uncertain due to case studies involving small patient numbers, confounding factors (eg, concurrent treatments), and a lack of animal studies. A recent study proposed danaparoid and heparin as potential VITT therapies because of their ability to disrupt VITT IgG-platelet factor 4 (PF4) binding. Here, we examined the effects of various anticoagulants (including unfractionated [UF] heparin, danaparoid, bivalirudin, fondaparinux, and argatroban), IVIg, and the FcγRIIa receptor-blocking antibody, IV.3. Our investigation focused on VITT IgG-PF4 binding, platelet activation, thrombocytopenia, and thrombosis. Danaparoid, at therapeutic doses, was the sole anticoagulant that reduced VITT IgG-PF4 binding, verified by affinity-purified anti-PF4 VITT IgG. Although danaparoid and high-dose UF heparin (10 U/mL) inhibited platelet activation, none of the anticoagulants significantly affected thrombocytopenia in our VITT animal model and all prolonged bleeding time. IVIg and all anticoagulants except UF heparin protected the VITT mice from thrombosis. Direct FcγRIIa receptor inhibition with IV.3 antibody is an effective approach for managing both thrombosis and thrombocytopenia in the VITT mouse model. Our results underscore the necessity of animal model investigations to inform and better guide clinicians on treatment choices. This study provides compelling evidence for the development of FcγRIIa receptor blockers to prevent thrombosis in VITT and other FcγRIIa-related inflammatory disorders.
引用
- Leung HHL, Ahmadi Z, Lee B, et al. Antithrombotic efficacy and bleeding risks of vaccine-induced immune thrombotic thrombocytopenia treatments. Blood Adv. 2024. PMID: 39293086. doi:10.1182/bloodadvances.2024013883
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。